Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12687416 | 0.90 | APP (0.63) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL1666128 | 0.88 | APP (0.68) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL2139655 | 0.84 | APP (0.54) | APPMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12980621 | 0.82 | MMP2 (0.63) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL11972979 | 0.82 | RORC (0.49) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL11972685 | 0.82 | APP (0.58) | APPMEN1KMT2ARAB9AGLA | |
| SCHEMBL2246561 | 0.82 | APP (0.63) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL9436073 | 0.82 | APP (0.63) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL8532307 | 0.82 | APP (0.67) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL11973313 | 0.81 | DYRK1A (0.46) | APPMMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-8927584-B2 | Synthesis of 2-(4-aminophenyl)benzothiazole derivatives and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-01-06 | — | — | US | disclosed |
| US-8680155-B2 | Synthesis and antitumor activity of novel bis(benzylidene-benzenamine)disulfides | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-03-25 | — | — | US | disclosed |
| US-8680155-B2 | Synthesis and antitumor activity of novel bis(benzylidene-benzenamine)disulfides | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-03-25 | — | — | US | disclosed |
| US-20140046290-A1 | SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-02-13 | — | — | US | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8592603-B2 | Synthesis of 2-(4-aminophenyl) benzothiazole derivatives and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-11-26 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120283475-A1 | SYNTHESIS AND ANTITUMOR ACTIVITY OF NOVEL BIS(BENZYLIDENE-BENZENAMINE)DISULFIDES | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-11-08 | — | — | US | disclosed |
| US-20120215154-A1 | SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-08-23 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283475-A1 | SYNTHESIS AND ANTITUMOR ACTIVITY OF NOVEL BIS(BENZYLIDENE-BENZENAMINE)DISULFIDES | SKP1, CDC25C, CCND1 | APP 3476/4885MMP2 1635/4885MMP9 2359/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | APP 4017/4885MMP2 1625/4885MMP9 2761/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | APP 4017/4885MMP2 1625/4885MMP9 2761/4885 |
| US-20140046290-A1 | SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF | CCNT1, PPOX, TPT1 | APP 3066/4885MMP2 538/4885MMP9 1134/4885 |
| US-20120215154-A1 | SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF | HCCS, PAH, PPOX | APP 4468/4885MMP2 2347/4885MMP9 3205/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | APP 4337/4885MMP2 2947/4885MMP9 3993/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | APP 4337/4885MMP2 2947/4885MMP9 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.